We are live on ! Find out more
PVMCV

Polaris Venture Management Co V Portfolio holdings

AUM $14.1M
1-Year Est. Return 121.41%
This Fund
S&P 500
This Quarter Est. Return
+3.14%
1 Year Est. Return
+121.41%
3 Year Est. Return
+281.18%
5 Year Est. Return
+1,023.01%
10 Year Est. Return
–
AUM
$176M
AUM Growth
+$48.7M
Cap. Flow
+$47.4M
Cap. Flow %
26.94%
Top 10 Hldgs %
99.86%
Holding
13
New
1
Increased
1
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
ATYR
aTyr Pharma
ATYR
+$447K

Top Sells

Rank Stock Value
1
CDLX icon
Cardlytics
CDLX
+$24.7M
2
FATE icon
Fate Therapeutics
FATE
+$6.39M
3
KALA icon
KALA BIO
KALA
+$3.23M
4
TTOO
T2 Biosystems, Inc
TTOO
+$3.09M
5
TRVN
Trevena, Inc.
TRVN
+$2.12M

Sector Composition

Rank Sector Weight
1 Communication Services 28.72%
2 Healthcare 22.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDLX icon
1
Cardlytics
CDLX
$22.1M
$50.5M 28.72%
150,807
-76,927
-34% -$24.7M
FATE icon
2
Fate Therapeutics
FATE
$293M
$17.7M 10.06%
1,139,783
-333,403
-23% -$6.39M
STIM icon
3
Neuronetics
STIM
$137M
$6.09M 3.46%
732,583
-9,706
-1% -$106K
RNAC icon
4
Cartesian Therapeutics
RNAC
$227M
$4.85M 2.76%
92,449
– –
KALA icon
5
KALA BIO
KALA
$13.6M
$4.55M 2.59%
479
-265
-36% -$3.23M
XFOR icon
6
X4 Pharmaceuticals
XFOR
$377M
$3.96M 2.25%
10,383
– –
GNCA
7
DELISTED
Genocea Biosciences, Inc.
GNCA
$714K 0.41%
246,078
– –
ATYR
8
aTyr Pharma
ATYR
$47.1M
$457K 0.26%
130,571
+121,244
+1,300% +$447K
PULM icon
9
Pulmatrix
PULM
$6.21M
$294K 0.17%
17,972
– –
DARE icon
10
Dare Bioscience
DARE
$18.6M
$254K 0.14%
27,187
– –
TRVN
11
DELISTED
Trevena, Inc.
TRVN
– –
-3,286
Closed -$2.12M
TTOO
12
DELISTED
T2 Biosystems, Inc
TTOO
– –
-368
Closed -$3.09M

Similar funds

IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
AG
Ashmore Group London, United Kingdom $16.3M AUM 57.83% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
CCM
Copernicus Capital Management San Francisco, California $8.26M AUM 37.91% 1-Year Est. Return
EIP
Edgbaston Investment Partners $20.3M AUM 35.98% 1-Year Est. Return
AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
OEP
Ocean Endowment Partners Chicago, Illinois $20.6M AUM 27.63% 1-Year Est. Return

Polaris Venture Management Co V's Q3 2019 Portfolio in Review

As of Q3 2019, Polaris Venture Management Co V held 13 positions worth $176M, up 38% from $127M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Polaris Venture Management Co V deployed $47.4M of net new capital in Q3 2019, opening 1 new position and adding to 1 existing holding.

By sector, the portfolio is most concentrated in Communication Services at 29% of assets, down from 46% a quarter earlier, followed by Healthcare.

On the sell side, the largest reduction was Cardlytics, an estimated $24.7M trimmed.

  • Polaris Venture Management Co V added most to aTyr Pharma in Q3 2019, an estimated $447K increase.
  • Polaris Venture Management Co V's biggest Q3 2019 reduction was Cardlytics, cutting an estimated $24.7M.
  • Polaris Venture Management Co V fully exited T2 Biosystems, Inc in Q3 2019, selling an estimated $3.09M.
  • Polaris Venture Management Co V's ten largest holdings make up 100% of its $176M portfolio in Q3 2019.
  • Polaris Venture Management Co V opened 1 new position and closed 2 in Q3 2019.
  • Polaris Venture Management Co V's portfolio value rose 38% quarter-over-quarter to $176M.

Based on Polaris Venture Management Co V's 13F filing for Q3 2019, filed 13 Nov 2019.